DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6rxwsj/the) has announced the addition of the "The Pharmaceutical Market - Czech Republic" report to their offering.
The recent measures proposed by the Czech Republic's Ministry of Health will, in all likelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursement ceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers' margins and shift some of the burden of healthcare spending onto the private sector.
The outcome of similar measures in Hungary and Poland strongly supports our view that the business environment for drugmakers will worsen if these proposals are adopted. It is patients who, ultimately, will suffer.
Risk/Reward Rating:
The Czech Republic retains its leading position in the CEE RRRs in Q1, after displacing Poland in our Q4 assessment. Despite leading in our regional RRR table, the outlook for growth for the Czech pharmaceutical market is not particularly robust, as a result of pricing pressure, impeded market entry and increasing generic substitution. An increase in VAT and a stringent reference pricing system have affected sales and hit manufacturers' margins respectively.
Competitive Landscape:
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Companies Mentioned
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis
- Pfizer
- Sanofi
- Walmark
- Zentiva (Sanofi)
For more information visit http://www.researchandmarkets.com/research/6rxwsj/the
